Table3_Colchicine efficacy comparison at varying time points in the peri-operative period for coronary artery disease: a systematic review and meta-analysis of randomized controlle... by Zhi-Yang Wei (16752897)

“…Administration at different periods had no significant effect on decreasing the occurrence of MACE, but when administered postoperatively, we advise continuous administration with a total daily dose of 0.5 mg to obtain the same benefit while minimizing the drug's side effects. …”

Table2_Colchicine efficacy comparison at varying time points in the peri-operative period for coronary artery disease: a systematic review and meta-analysis of randomized controlle... by Zhi-Yang Wei (16752897)

“…Administration at different periods had no significant effect on decreasing the occurrence of MACE, but when administered postoperatively, we advise continuous administration with a total daily dose of 0.5 mg to obtain the same benefit while minimizing the drug's side effects. …”

Table1_Colchicine efficacy comparison at varying time points in the peri-operative period for coronary artery disease: a systematic review and meta-analysis of randomized controlle... by Zhi-Yang Wei (16752897)

“…Administration at different periods had no significant effect on decreasing the occurrence of MACE, but when administered postoperatively, we advise continuous administration with a total daily dose of 0.5 mg to obtain the same benefit while minimizing the drug's side effects. …”

Status (A) and duration (B) of breast feeding among participants. by Sara Saleh (6733619)

Induction level of the ORFs and the number of the regulated HITS. by Mohamad Karaky (8910497)

Subjects:

Identification of TFBS in the promoter regions of S100A8 and S100A9. by Mohamad Karaky (8910497)

Subjects:

Proposed model of S100A8/9 induction. by Mohamad Karaky (8910497)

Subjects:

Impact of PTGIR expression on the CP (S100A8/9 dimer) protein levels in THP1. by Mohamad Karaky (8910497)

Subjects:

Flow chart of the expression-based functional screen, with validation steps. by Mohamad Karaky (8910497)

Subjects:

Transcription factor binding site analysis of HITS upregulated by different IBD-ORFs by PRIMA-EXPANDER. by Mohamad Karaky (8910497)

Subjects:

Selection of genes to include in expression screen. by Mohamad Karaky (8910497)

Subjects:

The impact of different concentrations of PTGIR antagonist on CP genes expression in THP1. by Mohamad Karaky (8910497)

Subjects:

Generation of a hiPSC-derived monocytic model. by Mohamad Karaky (8910497)

Subjects:

S4 Table - by Mohamad Karaky (8910497)

Subjects:

S3 Table - by Mohamad Karaky (8910497)

Subjects:

Shared impact on transcriptome for the ORFs ETS2 and ZBTB40. by Mohamad Karaky (8910497)

Subjects:

Transcription factor binding site analysis of HITS upregulated by different IBD-ORFs by gProfiler. by Mohamad Karaky (8910497)

Subjects:

Shared impact on transcriptome for the ORFs PTGIR, NFKB1, SLC39A11 and ZBTB40. by Mohamad Karaky (8910497)

Subjects:

Impact of LPS on PTGIR expression in THP-1. by Mohamad Karaky (8910497)

Subjects:

Numeric data for the graphs in the main and the supporting figures. by Mohamad Karaky (8910497)

Subjects: